Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the presentation of a Trial in Progress poster for its Phase 1 clinical trial of CTIM-76 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial focuses on CTIM-76, a Claudin 6 x CD3 T cell engager, and is being evaluated for its safety and efficacy in treating CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The study, which began dosing its first patient in January 2025, is currently in the dosing cohort 3 phase. It is an open-label, dose escalation and expansion study expected to enroll up to 70 patients. The company plans to share initial data in the first half of 2026. Presentation materials will be available on Context Therapeutics' website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.